Moleculin Biotech Inc (NASDAQ: MBRX) on Monday, soared 14.54% from the previous trading day, before settling in for the closing price of $0.55. Within the past 52 weeks, MBRX’s price has moved between $0.25 and $4.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 26.36%. The company achieved an average annual earnings per share of 75.21%. With a float of $21.99 million, this company’s outstanding shares have now reached $24.10 million.
Let’s determine the extent of company efficiency that accounts for 17 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Moleculin Biotech Inc (MBRX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Moleculin Biotech Inc is 8.74%, while institutional ownership is 6.13%. The most recent insider transaction that took place on Jun 23 ’25, was worth 100,000. In this transaction Chief Financial Officer of this company bought 270,270 shares at a rate of $0.37, taking the stock ownership to the 287,587 shares. Before that another transaction happened on Jun 23 ’25, when Company’s CEO and President bought 675,675 for $0.37, making the entire transaction worth $250,000. This insider now owns 743,607 shares in total.
Moleculin Biotech Inc (MBRX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 75.21% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 42.60% during the next five years compared to 26.36% growth over the previous five years of trading.
Moleculin Biotech Inc (NASDAQ: MBRX) Trading Performance Indicators
Moleculin Biotech Inc (MBRX) is currently performing well based on its current performance indicators. A quick ratio of 1.35 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.80, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.36 in one year’s time.
Technical Analysis of Moleculin Biotech Inc (MBRX)
Looking closely at Moleculin Biotech Inc (NASDAQ: MBRX), its last 5-days average volume was 28.59 million, which is a jump from its year-to-date volume of 4.75 million. As of the previous 9 days, the stock’s Stochastic %D was 67.77%.
During the past 100 days, Moleculin Biotech Inc’s (MBRX) raw stochastic average was set at 19.29%, which indicates a significant decrease from 80.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0836 in the past 14 days, which was lower than the 0.1068 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7177, while its 200-day Moving Average is $1.5195. However, in the short run, Moleculin Biotech Inc’s stock first resistance to watch stands at $0.7296. Second resistance stands at $0.8292. The third major resistance level sits at $0.9454. If the price goes on to break the first support level at $0.5138, it is likely to go to the next support level at $0.3976. Now, if the price goes above the second support level, the third support stands at $0.2980.
Moleculin Biotech Inc (NASDAQ: MBRX) Key Stats
Market capitalization of the company is 15.19 million based on 14,127K outstanding shares. Right now, sales total 0 K and income totals -21,760 K. The company made 0 K in profit during its latest quarter, and -6,440 K in sales during its previous quarter.
